Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 27, Issue 24, p.3881-6 (2009)


2009, Antigens, Neoplasm, Breast Neoplasms, Center-Authored Paper, Chemotherapy, Adjuvant, Chromosomes, Human, Pair 17, DNA Topoisomerases, Type II, DNA-Binding Proteins, Doxorubicin, Female, GENE AMPLIFICATION, Gene Dosage, Human Biology Division, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Neoplasm Staging, Receptor, erbB-2, Shared Resources, Specimen Processing Core Facility, Tissue Array Analysis, Treatment Outcome


Amplification and deletion of the TOP2A gene have been reported as positive predictive markers of response to anthracycline-based therapy. We determined the status of the HER2 and TOP2A genes in a large cohort of breast cancer patients treated with adjuvant doxorubicin (A) and cyclophosphamide (C).